Indian drugmaker Dr Reddy's shares slide

Dr Reddy's Shares Plunge 7% After Disappointing Q3 Earnings
Dr Reddy's Laboratories shares dropped nearly 7% on Friday after the company reported a slight increase in net profit for the third quarter, disappointing investors.
Dr Reddy’s shares plummet 4.4% in the wake of logging modest Q3 growth
Dr Reddy’s Laboratories reports 2% increase in net profit, attributing growth to new acquisitions and product launches.
Indian drugmaker Dr Reddy's shares slide after Q3 profit miss
Shares of Dr Reddy's Laboratories dropped 6% in early trade on Friday, a day after the company reported a third-quarter profit that fell short of market estimates due to lower sales and pricing pressures in the key North American market.
Dr. Reddy's Laboratories Q3 Results: Profit Rises 2%, But Misses Estimates
Dr. Reddy's Laboratories Ltd.'s profit rose 2% in the third quarter of the current financial year, but missed analysts' estimates.
Dr. Reddy's Laboratories shares fall over 6% post subdued Q3 show; analysts divided
Dr. Reddy's Laboratories shares in Friday's trade slipped by over 6 per cent in early trade to the day's low price of Rs 1,203.6 after the pharma major posted weak performance during the December quarter.
Dr Reddy's shares tank 7% post Q3 results; should you buy, sell or hold?
Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market capitalisation slipping below Rs 1 lakh crore mark.
Dr Reddy’s Laboratories Q3 net profit zooms ~3%
The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.
Dr Reddy's Laboratories Reports Modest Profit Rise Amid Revenue Surge
Dr Reddy's Laboratories reported a 2% increase in net profit to Rs 1,413 crore for the third quarter ending December 2024. The company's revenue surged to Rs 8,359 crore, driven by new business acquisitions and launches.
Indian drugmaker Dr Reddy's misses Q3 profit view on weak pricing in US
BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, hurt by pricing pressure in the competitive North American market,
Dr Reddy’s Q3 profit rises 2%
Hyderabad: Despite posting record revenues, pharma major Dr Reddy's Laboratories on Thursday reported a marginal 2% increase in consolidated profit after tax (PAT attributable to equity holders) at 1,
Dr Reddy's Laboratories CEO: 'very positive outlook' for Indian pharma industry despite Trump 2.0
CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...
Dr. Reddy's Laboratories underperforms Thursday when compared to competitors
Dr. Reddy's Laboratories Ltd. 500124 shares inched down 0.54% to 1,289.35 Indian rupees Thursday, on what proved to be an all ...
Dr Reddy's stock plunges 6% as Revlimid revenue concerns loom large despite positive Q3 earnings
Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally up from $161 ...
Healthcare stocks rally over 2% as CLSA upgrades Dr Lal Pathlabs and Aurobindo; DRL drops on downgrade
Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...